Literature DB >> 18799783

Neurodegeneration associated with genetic defects in phospholipase A(2).

A Gregory1, S K Westaway, I E Holm, P T Kotzbauer, P Hogarth, S Sonek, J C Coryell, T M Nguyen, N Nardocci, G Zorzi, D Rodriguez, I Desguerre, E Bertini, A Simonati, B Levinson, C Dias, C Barbot, I Carrilho, M Santos, I Malik, J Gitschier, S J Hayflick.   

Abstract

OBJECTIVE: Mutations in the gene encoding phospholipase A(2) group VI (PLA2G6) are associated with two childhood neurologic disorders: infantile neuroaxonal dystrophy (INAD) and idiopathic neurodegeneration with brain iron accumulation (NBIA). INAD is a severe progressive psychomotor disorder in which axonal spheroids are found in brain, spinal cord, and peripheral nerves. High globus pallidus iron is an inconsistent feature of INAD; however, it is a diagnostic criterion of NBIA, which describes a clinically and genetically heterogeneous group of disorders that share this hallmark feature. We sought to delineate the clinical, radiographic, pathologic, and genetic features of disease resulting from defective phospholipase A(2).
METHODS: We identified 56 patients clinically diagnosed with INAD and 23 with idiopathic NBIA and screened their DNA for PLA2G6 mutations.
RESULTS: Eighty percent of patients with INAD had mutations in PLA2G6, whereas mutations were found in only 20% of those with idiopathic NBIA. All patients with two null mutations had a more severe phenotype. On MRI, nearly all mutation-positive patients had cerebellar atrophy, and half showed brain iron accumulation. We observed Lewy bodies and neurofibrillary tangles in association with PLA2G6 mutations.
CONCLUSION: Defects in phospholipase A(2) lead to a range of phenotypes. PLA2G6 mutations are associated with nearly all cases of classic infantile neuroaxonal dystrophy but a minority of cases of idiopathic neurodegeneration with brain iron accumulation, and genotype correlates with phenotype. Cerebellar atrophy predicts which patients are likely to be mutation-positive. The neuropathologic changes that are caused by defective phospholipase A(2) suggest a shared pathogenesis with both Parkinson and Alzheimer diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799783      PMCID: PMC2676964          DOI: 10.1212/01.wnl.0000327094.67726.28

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome).

Authors:  Susan J Hayflick
Journal:  J Neurol Sci       Date:  2003-03-15       Impact factor: 3.181

2.  Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria.

Authors:  N Nardocci; G Zorzi; L Farina; S Binelli; W Scaioli; C Ciano; L Verga; L Angelini; M Savoiardo; O Bugiani
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Cellular responses to excess phospholipid.

Authors:  I Baburina; S Jackowski
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

4.  Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients.

Authors:  L Farina; N Nardocci; M G Bruzzone; L D'Incerti; G Zorzi; L Verga; M Morbin; M Savoiardo
Journal:  Neuroradiology       Date:  1999-05       Impact factor: 2.804

5.  Neuroaxonal dystrophy with dystonia and pallidal involvement.

Authors:  A Simonati; C Trevisan; A Salviati; N Rizzuto
Journal:  Neuropediatrics       Date:  1999-06       Impact factor: 1.947

6.  Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury.

Authors:  K L Newell; P Boyer; E Gomez-Tortosa; W Hobbs; E T Hedley-Whyte; J P Vonsattel; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  1999-12       Impact factor: 3.685

7.  Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.

Authors:  Paul T Kotzbauer; Benoit I Giasson; Alexxai V Kravitz; Lawrence I Golbe; Margery H Mark; John Q Trojanowski; Virginia M-Y Lee
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

8.  Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.

Authors:  Susan J Hayflick; Shawn K Westaway; Barbara Levinson; Bing Zhou; Monique A Johnson; Katherine H L Ching; Jane Gitschier
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

Review 9.  In vivo diagnosis of Hallervorden-Spatz disease.

Authors:  J R Ostergaard; T Christensen; K N Hansen
Journal:  Dev Med Child Neurol       Date:  1995-09       Impact factor: 5.449

10.  Infantile neuroaxonal dystrophy.

Authors:  J Aicardi; P Castelein
Journal:  Brain       Date:  1979-12       Impact factor: 13.501

View more
  100 in total

1.  Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2.

Authors:  Ronen Spiegel; Ophry Pines; Asaf Ta-Shma; Efrat Burak; Avraham Shaag; Jonatan Halvardson; Shimon Edvardson; Muhammad Mahajna; Shamir Zenvirt; Ann Saada; Stavit Shalev; Lars Feuk; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2012-03-09       Impact factor: 11.025

Review 2.  Genetics of neurodegeneration with brain iron accumulation.

Authors:  Allison Gregory; Susan J Hayflick
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 3.  Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes.

Authors:  Manju A Kurian; Susan J Hayflick
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

Review 4.  The neuropathology of neurodegeneration with brain iron accumulation.

Authors:  Michael C Kruer
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

Review 5.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

6.  Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia.

Authors:  A Deik; B Johannes; J C Rucker; E Sánchez; S E Brodie; E Deegan; K Landy; Y Kajiwara; S Scelsa; R Saunders-Pullman; C Paisán-Ruiz
Journal:  J Neurol       Date:  2014-09-30       Impact factor: 4.849

7.  Severe disturbance in the Ca2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6.

Authors:  Mikhail Strokin; Kevin L Seburn; Gregory A Cox; Kimberly A Martens; Georg Reiser
Journal:  Hum Mol Genet       Date:  2012-03-22       Impact factor: 6.150

8.  Cerebral Iron Accumulation Is Not a Major Feature of FA2H/SPG35.

Authors:  Cecilia Marelli; Mustafa A Salih; Karine Nguyen; Martial Mallaret; Nicolas Leboucq; Hamdy H Hassan; Nathalie Drouot; Pierre Labauge; Michel Koenig
Journal:  Mov Disord Clin Pract       Date:  2015-02-18

Review 9.  Clinical and genetic delineation of neurodegeneration with brain iron accumulation.

Authors:  A Gregory; B J Polster; S J Hayflick
Journal:  J Med Genet       Date:  2008-11-03       Impact factor: 6.318

10.  Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.

Authors:  Laura A Engel; Zheng Jing; Daniel E O'Brien; Mengyang Sun; Paul T Kotzbauer
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.